DR. ROGER JOSEPH HAJJAR, MD
Medical Practice at Gustave L Levy Pl, New York, NY
License number
New York 76633
Category
Osteopathic Medicine
Type
Cardiovascular Disease
License number
New York 242450
Category
Medical Practice
Type
Specialist
Address
Address
1 Gustave L Levy Pl, New York, NY 10029
Phone
(212) 427-1540
(212) 410-7196 (Fax)
(212) 987-3100
(212) 731-5210 (Fax)
(212) 410-7196 (Fax)
(212) 987-3100
(212) 731-5210 (Fax)
Personal information
See more information about ROGER JOSEPH HAJJAR at radaris.comName
Address
Phone
175 96Th St, New York, NY 10128
Professional information
See more information about ROGER JOSEPH HAJJAR at trustoria.com
Professor Of Medicine At Mount Sinai School Of Medicine
Professor Of Medicine At Mount Sinai School Of Medicine
Position:
Professor of Medicine at Mount Sinai School of Medicine
Location:
Greater New York City Area
Industry:
Hospital & Health Care
Work:
Mount Sinai School of Medicine
-
Professor of Medicine
Dr. Roger J Hajjar, New York NY - MD (Doctor of Medicine)
Dr. Roger J Hajjar, New York NY - MD (Doctor of Medicine)
Specialties:
Cardiology
Address:
5 E 98Th St SUITE 3RD, New York 10029
(212) 241-5586 (Phone), (212) 876-1493 (Fax)
KUKIN, MARRICK L, M.D.
1 Gustave L Levy Pl SUITE 1030, New York 10029
(800) 542-5760 (Phone), (212) 369-3269 (Fax)
(212) 241-5586 (Phone), (212) 876-1493 (Fax)
KUKIN, MARRICK L, M.D.
1 Gustave L Levy Pl SUITE 1030, New York 10029
(800) 542-5760 (Phone), (212) 369-3269 (Fax)
Certifications:
Cardiovascular Disease, 1997, Internal Medicine, 1993
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Harvard Medical School
Graduated: 1990
Massachusetts General Hospital
Harvard Medical School
Graduated: 1990
Massachusetts General Hospital
Treating Heart Failure And Ventricular Arrhythmias
Treating Heart Failure And Ventricular Arrhythmias
US Patent:
2009023, Sep 24, 2009
Filed:
Feb 23, 2009
Appl. No.:
12/391257
Inventors:
Federica Del Monte - Boston MA, US
Roger J. Hajjar - New York NY, US
Fabrice Prunier - Angers, FR
Roger J. Hajjar - New York NY, US
Fabrice Prunier - Angers, FR
International Classification:
A61K 31/7088, A61K 31/7105, A61K 31/711
US Classification:
514 44 R
Abstract:
The present invention provides methods and materials for treating heart disorders, including heart failure and arrhythmia, by enhancing SERCA2a activity. Heart cells in a subject can be treated, for example, by introducing, into the heart of the subject, an adeno-associated virus subtype 6 (AAV6) viral delivery system that includes a functional nucleic acid encoding SERCA2a. For example, the functional nucleic acid encodes a non-viral therapeutic protein, thereby treating the subject.
Roger Joseph Hajjar, New York NY
Roger Joseph Hajjar, New York NY
Specialties:
Internal Medicine, Cardiovascular Disease, Cardiology
Work:
Mt Sinai Hospital
5 E 98Th St, New York, NY 10029 New York University - Mount Sinai
1 Gustave L Levy Pl, New York, NY 10029
5 E 98Th St, New York, NY 10029 New York University - Mount Sinai
1 Gustave L Levy Pl, New York, NY 10029
Education:
Harvard University(1990)
Roger Joseph Hajjar, New York NY
Roger Joseph Hajjar, New York NY
Specialties:
Internist
Address:
1 Gustave L Levy Pl, New York, NY 10029
5 E 98Th St, New York, NY 10029
5 E 98Th St, New York, NY 10029
Education:
Harvard Medical School - Doctor of Medicine
Massachusetts General Hospital - Fellowship - Cardiology
Massachusetts General Hospital - Residency - Internal Medicine
Massachusetts General Hospital - Fellowship - Cardiology
Massachusetts General Hospital - Residency - Internal Medicine
Rna Interference For The Treatment Of Heart Failure
Rna Interference For The Treatment Of Heart Failure
US Patent:
8404658, Mar 26, 2013
Filed:
Dec 23, 2008
Appl. No.:
12/811306
Inventors:
Roger J. Hajjar - New York NY, US
Wolfgang Ch. Poller - Falkensee, DE
Henry Fechner - Luckau, DE
Wolfgang Ch. Poller - Falkensee, DE
Henry Fechner - Luckau, DE
Assignee:
NanoCor Therapeutics, Inc. - Chapel Hill NC
International Classification:
C12N 15/11
US Classification:
514 44A
Abstract:
The present invention relates to targeted RNAi for the treatment of heart failure by modulating defective cardiac Ca homeostasis via decreasing expression or activity of phospholamban (PLB) using adeno-associated virus (AAV) transfection of cardiomyocytes. Methods for decreasing ventricular arrhythmias, as well as methods for overall improvement of survival from heart failure in subjects are also disclosed. Further, the present invention provides methods which can be used to diagnose susceptibility to treatment by RNAi, and includes pharmaceutical compositions, kits and vectors including an RNAi sequence.
Modulating Phosphatase Activity In Cardiac Cells
Modulating Phosphatase Activity In Cardiac Cells
US Patent:
2008012, May 29, 2008
Filed:
Sep 8, 2005
Appl. No.:
11/662439
Inventors:
Roger J. Hajjar - New York NY, US
Federica Del Monte - Boston MA, US
Evangelia Kranias - Cincinnati OH, US
Federica Del Monte - Boston MA, US
Evangelia Kranias - Cincinnati OH, US
International Classification:
A61K 31/7052, A61P 9/04, C12N 15/63
US Classification:
514 44, 4353201, 435440
Abstract:
Expression of a phosphatase inhibitor in heart cells can be used to treat cardiac disorders, e.g., heart failure. Decreasing phosphatase activity can improve β-adrenergic responsiveness.